-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Tarsus Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2019 to Q2 2024.
- Tarsus Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $12K, a 99.1% decline year-over-year.
- Tarsus Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $6.3M, a 31.7% increase year-over-year.
- Tarsus Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $7.27M, a 1077% increase from 2022.
- Tarsus Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $617K.
- Tarsus Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.62M, a 959% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)